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C C Barreto PhD‡, S Chen PhD** and E C Sabino MD PhD*‡
*Department of Infectious Disease, Faculty of Medicine, University of Sa˜o Paulo; †STD/AIDS Reference and Training Center;
‡Fundaca˜o Pro-Sangue, Hemocentro; §Department of Translational Medicine, Federal University of Sa˜o Paulo, Sa˜o Paulo, Brazil;
San Francisco Department of Public Health, San Francisco, CA, USA
Summary: Most of the antiretroviral (ARV) studies in Brazil have been reported in treatment-experienced and naive patients rather
than in the setting of treatment interruption (TI). In this study, we analysed reasons given for TI and resistance mutations occurring in
150 HIV-1-infected patients who underwent TI. Of the patients analysed, 110 (73.3%) experienced TI following medical advice, while
the remaining patients stopped antiretroviral therapy (ART) of their own accord. The main justifications for TI were: ARV-related
toxicities (38.7%), good laboratory parameters (30%) and poor adherence (20%). DNA sequencing of the partial pol gene was
successful in 137 (91.3%) patients, of whom 38 (27.7%) presented mutations conferring ARV resistance. A higher viral load prior to TI
correlated with drug resistance (P, 0.05). Our results demonstrate that there are diverse rationales for TI and that detection of
resistant strains during TI most likely indicates a fitter virus than the wild type. High viral loads coupled with unprotected sex in
this group could increase the likelihood of transmission of drug-resistant virus. Thus, treating physicians should be alerted to
this problem when the use of ARVs is interrupted.
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INTRODUCTION
Brazil has the second highest number of HIV-1 cases in the
Americas, after the USA, with an estimated number of
730,000 HIV-1/AIDS cases at the beginning of 2008 (2008
Report on the Global AIDS Epidemic). In 1996, the Brazilian
Ministry of Health (BMH) adopted a policy for controlling
the HIV-1 epidemic by providing antiretroviral (ARV) drugs
for all HIV-1-infected patients who needed therapy.
Subsequently, national AIDS mortality has fallen by 50% and
HIV/AIDS hospitalizations have fallen by 70–80%.1 In
addition, because of the increase in access to antiretroviral
therapy (ART), from approximately 38,000 patients in 1997 to
180,000 in 2006,2 the average survival time of Brazilian patients
with HIV/AIDS seeking medical care has increased from less
than six months to at least ﬁve years (The World Health
Organization Report, 2004).
The successful use of ARV drugs did not come without
increased cost and substantial side-effects that may jeopardize
the success of current therapeutic options.3 Besides treatment
toxicities, there are several factors that contribute to treatment
failure, including viral genetics, adherence to drug regimens
and emergence of drug-resistant variants.4,5 Evidence for disse-
mination of drug-resistant variants in Brazil stems from reports
of primary resistance in recently infected individuals (0–
12.7%), as well as those with longstanding infections (5%).5–8
Difﬁculties encountered in treated patients are well known
and include problems due to emergence of drug-resistant
strains and decreased tolerance to side-effects of therapy. This
has led to changes in the guidelines for initiating treatment.
Updates from the International AIDS Society – USA rec-
ommend initiation of ART for symptomatic patients with estab-
lished disease, regardless of CD4 cell count, and for all
asymptomatic individuals and those with speciﬁc conditions
and co-morbidities with CD4 counts less than or equal to
500 cells/mL.9
Some scientists have proposed to evaluate structured treat-
ment interruption (TI) in individuals to avoid the complications
involved in the administration of continuous ART.10–13
Although TI was never explicitly recommended by the treat-
ment guidelines from the BMH, it became a frequent and inevi-
table option used by Brazilian clinicians before the results from
SMART14 and other studies were published.15,16
Although ART has been provided without charge to all
HIV-1-infected individuals, much of the focus on ARV resist-
ance in Brazil has been limited to treatment-naive patients,
therapy-experienced patients or persons who have been
infected with resistant virus rather than acquiring it following
TI.8,17,18 A previous unpublished study conducted in 2001 in
Sa˜o Paulo, Brazil, aimed at evaluating drug use and drug
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resistance in 170 HIV-infected outpatients found that approxi-
mately 10% of these patients eventually switched to long-term
TI (Jamal L, personal communication). The prevalence and
reasons for TI in Brazilian HIV-1-infected patients with treat-
ment failure and multidrug-resistant virus are largely
unknown. Prompted by these needs, we designed this cross-
sectional study to better understand the reasons for TI in
routine clinical practice and the consequences in 150
HIV-infected adults who had stopped taking treatment for at
least six months. We also attempted to explore whether the
various justiﬁcations for TI, together with clinical, laboratory
and epidemiological variables, are linked to the emergence of
genotypic drug-resistance mutations.
MATERIALS AND METHODS
Patients
We enrolled 150 HIV-1-infected patients who were admitted to
the ‘Casa da AIDS’, an outpatient clinic, and Sao Paulo State
STD/AIDS Reference and Training Center (CRT-DST/AIDS),
Brazil, between April 2002 and June 2005. The two sites are
responsible for the care of four to ﬁve thousand HIV-infected
patients. Eligibility criteria were restricted to adults at least 18
years of age who had been on combination ART for more
than six months and had interrupted their therapy for at least
six months upon study entry. The median time between the
start of TI and genotype testing was 338 days, with a range
of 130–532 days. After providing written, informed consent,
participants were interviewed about their sociodemographic
and epidemiological status. Clinical data, laboratory values
and types of ART received throughout their care were acquired
by reviewing the medical records of all participants. This study
was approved by the Institutional Ethical Research Board in the
CRT-DST/AIDS and Hospital das Clinicas da FMUSP.
Nucleic acid extraction, amplification and
sequencing
Regardless of viral loads, DNA was extracted from patients’
peripheral blood mononuclear cells (PBMCs) using the
QIAamp blood kit (Qiagen GmbH, Hilden, Germany) as per
the manufacturer’s instructions. HIV-1 partial pol proviral
DNA was ampliﬁed from puriﬁed genomic DNA by the poly-
merase chain reaction (PCR) as previously described.8 Both
DNA complementary strands were sequenced directly from
puriﬁed PCR products by using a variety of internal sequence-
speciﬁc primers, ﬂuorescent-dye terminators and Taq polymer-
ase on an automated sequencer (ABI 3100, Applied Biosystems,
Inc, Foster City, CA, USA). Data from the sequenced fragments
were edited, assembled into contiguous sequences with
minimum overlap of 20 bp and a minimal 85–100% mismatch,
and a consensus of both strands was generated by the
Sequencher program (Gene Code Corp, Ann Arbor, MI,
USA). The sequence was submitted to the Stanford HIV-SEQ
programme (http://hivdb.stanford.edu)19 where it was inter-
preted as having low-, intermediate- or high-level resistance
to the individual drugs. Brieﬂy, the programme compares user-
submitted protease and reverse transcriptase (RT) sequences
with a consensus reference sequence and uses the nucleotide
distances as query parameters for interrogating the viral RT
and protease sequence database.
Statistical analysis
Data were entered and validated with EpiData version 3.1
(EpiData Association, Odense, Denmark). Qualitative par-
ameters were given as proportions (percentages). Differences
were calculated using the chi-square test for proportions and
the non-parametric test (Mann-Whitney U test) for quantitative
analysis. Statistical analyses were performed using Stata version
9.0 software (StataCorp, College Station, TX, USA). Test results
were considered signiﬁcant for a two-sided P value ,0.05.
RESULTS
The study group was composed of 150 HIV-1-infected partici-
pants, of whom 92 (61.3%) were men (median age, 37 years,
range 22–63 years). Most male participants (77; 51.3%) were
men who have sex with men (MSM) and only nine subjects
had a history of injection drug use. The number of patients
who had unprotected sexual contact during the 12 months
prior to the study was 56 (37.3%). A total of 130 (86.7%) of
the subjects had had sex with two or more partners. All partici-
pants but one had at least six years of formal education. The
median time between the diagnosis of HIV infection and the
cessation of therapy was 6.2 years (range 2.7–7.8 years). The
median time on ART was 4.1 years (range 2.5–5.8 years), and
108 (72%) individuals had been treated with two or more regi-
mens. An AIDS-related opportunistic disease was diagnosed in
55 (37.0%) patients previously, of whom 35 had a TI planned by
their physician. The reasons for TI within this group were:
medication side-effects in 18 patients, satisfactory laboratory
response in nine patients, poor compliance to ART in ﬁve
patients and more than one reason in three patients. After treat-
ment cessation, AIDS-related illnesses developed in ﬁve out of
the 55 AIDS cases and in only one out of the 95 (63%) AIDS-free
participants.
Although plasma HIV-1 RNA remains the material of choice
for the determination of drug-resistant mutations and guiding
therapeutic decisions20,21 the proviral PBMC DNA sequence
can contain a variety of multiple archived mutations that are
not present in plasma, particularly among patients undergoing
TI or those with previous episodes of treatment failure due to
selection of mutations found in the cellular compartments.22,23
This, combined with the stability of DNA compared with
RNA, and the fact that HIV DNA recovered from the proviral
compartment can reliably be used for the determination of
drug resistance mutations in patients receiving ART24–28 inﬂu-
enced our decision to use proviral DNA in this study.
Of the 150 HIV-1-infected participants, samples from 137
(91.3%) were ampliﬁed and the protease/RT genes sequenced,
enabling subtype classiﬁcation and drug resistance. The
HIV-1 subtypes of the studied subjects were distributed in the
following manner: 123 clade B (89.8%), nine clade F1 (6.6%),
four B/F recombinant strains (2.9%) and two clade C (1.4%).
As shown in Table 1, drug resistance-associated mutations
did not signiﬁcantly correlate with the year of ART initiation,
previous and last ART regimen or drug adherence.
Analysis of TI among the 137 subjects showed that 101
(73.7%) of the patients had interrupted treatment following
medical advice while the remaining stopped of their own
accord. The reasons given for TI were: 56 (40.8%) had
ARV-related side-effects, 40 (29.2%) had satisfactory laboratory
responses and/or started therapy based on criteria that were no
longer used, 28 (20.4%) had poor adherence, 11 (8.0%) had two
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or more of the aforementioned reasons and two (1.4%) women
became pregnant. Among the sequenced samples, 38 (27.7%)
revealed mutations associated with resistance to at least one
of the ARV drug classes. Twenty-nine of them had nucleoside
reverse transcriptase inhibitor (NRTI)-associated mutations,
15 had non-nucleoside reverse transcriptase inhibitor
(NNRTI)-associated mutations and only ﬁve had protease
inhibitor-associated mutations (Table 2). Most of the patients
exhibited few mutations, but some presented a complete
pattern of drug resistance. A mutation at codon K103, which
confers a high level of resistance to nevirapine, delavirdine
and efavirenz, was detected in nine patients. A mutation at
K103 was also found in association with M184V in one case.
Additionally, the amino acid substitution M184V, which is
associated with high-level resistance to emtricitabine and lami-
vudine and low-level resistance to abacavir, was detected in
three patients, one of whom had been off treatment for at
least 28 months. Strong positive correlation between detectable
viral load and drug resistance was evident before TI (P ¼ 0.004)
but not during therapy initiation or before the genotypic test, as
shown in Table 3.
DISCUSSION
Scheduled TI has been suggested as an alternative therapeutic
option to reduce both the burden of toxicity caused by prolonged
exposure to ARV and costs of the medication. Recently, large
cohorts like SMART, Staccato and TRIVACAN14–16 have
evaluated this strategy. The SMART and TRIVICAN studies
were terminated prior to completion due to high morbidity
events in the intermittent therapy group that were not detected
in the STACCATO study. The absolute risk of disease pro-
gression was low in those trials, making the debate about the
use of TI in current practice open for patients with difﬁculties in
maintaining therapy.29 Indeed, the BMH 2010 consensus has
suggested TI in patients with high CD4 and low adherence to
ART (Recommendations for ART in adults and adolescents infected
with HIV. Brası´lia: Ministry of Health, 2010). Our results showed,
even before the results of these studies were published, that
Brazilian physicians had been forced to interrupt drug therapy
because of unpleasant adverse effects and non-adherence to
ART, even though this practice had not been indicated by the
BMH at that time. However, for 30% of the patients, there were
no other reasons besides satisfactory laboratory parameters,
allowing them to defer therapy as per more recent guidelines.
It has been well established that emergence of resistance
mutations in the absence of drug selection pressure can
decrease both viral replicative capacity and ﬁtness.30,31
Furthermore, earlier studies have provided enough evidence
of an apparent replacement of HIV-resistant isolates in
plasma by wild-type viruses in a majority of patients who
undergo TI after the development of resistant viruses.11,32,33
The systematic study of the disappearance of HIV drug
resistance mutations in patients stopping treatment has only
recently received attention. Trignetti et al.34 found that mutations
associated with NRTI resistance exhibited different dynamic
rates of disappearance during TI. For instance, the disappearance
ofM184I/Vmutations inHIVRNAwas reported to occur rapidly
after TI (median survival time,4.3months) in amajority (91.5%;
87/95) of their patients and coincided with a surge of wild-type
strains. In our current ﬁndings, we showed that M184 and
K103 resistance mutations persisted in HIV-integrated DNA
during TI in four and nine patients, respectively. However, as
we do not know how many patients had these mutations at the
initiation of ART, it is difﬁcult to know the signiﬁcance of this
ﬁnding in the population described. It is noteworthy that in
patient 29, virus expressing M184V persisted for at least 13
months after treatment cessation. This relative longevity of
M184V was contrary to the usual rapid disappearance of this
mutation in patients undergoing TI. It is possible that long-lived
cellular compartments had been fuelled early in infection with
the same mutated strains and had not been replaced.35
Alternatively, this patient may have acquired viruses containing
the M184V mutation during primary infection which makes
it less likely to revert to wild type since the transmission of
resistant strains is usually clonal.36
One of the aims of this study was to evaluate a resistance
mutation pattern among these types of patients. We have
asked clinicians from two HIV outpatient centres to request a
Table 1 Treatment characteristics and antiretroviral resist-
ance among the successfully genotyped samples in 137
patients during therapeutic interruption
ARV resistance
No Yes
Characteristics n (%) n (%) P value No
Year of ART initiation 0.2
1981–1996 26 (68.4) 12 (31.6) 38
1997–2001 73 (74.5) 25 (25.5) 98
Number of previous ART
regimens
0.9
1 27 (71.0) 11 (28.0) 38
2 25 (71.4) 10 (28.6) 35
3 47 (73.4) 17 (26.6) 64
First ART regimen used 0.3
NRTI 78 (72.9) 29 (27.1) 107
NRTI þ NNRTI 5 (100.0) 0 5
NRTI þ PI† 15 (62.5) 9 (37.5) 24
NRTI þ NNRTI þ PI 1 (1.0) 0 1
Last ART regimen used 0.6
NRTI 33 (68.7) 15 (31.3) 48
NRTI þ NNRTI 35 (47.5) 12 (25.5) 47
NRTI þ PI 28 (71.8) 11 (28.2) 39
NRTI þ NNRTI þ PI 3 (100.0) 0 3
CD4 nadir (cells per mm3) 0.1
50 5 (50.0) 5 (50.0) 10
51–200 7 (87.5) 1 (12.5) 8
201 87 (73.1) 32 (26.9) 119
Previous ART interruption 0.1
Yes 43 (66.5) 22 (33.5) 65
No 56 (77.8) 16 (22.2) 72
Decision for treatment
interruption
0.4
Medical recommendation 75 (74.3) 26 (25.7) 101
Patient’s own decision 24 (66.7) 12 (33.3) 36
Reasons for interruption 0.5
Poor adherence 19 (67.9) 9 (32.1) 28
Started ART based on
criteria that were no
longer used/satisfactory
laboratory parameters
28 (70.0) 12 (30.0) 40
Unable to endure ART
side-effects
40 (71.4) 16 (28.5) 56
Pregnant 2 (100.0) 0 2
Multiple reasons 10 (90.9) 1 (9.0) 11
ARV ¼ antiretroviral; ART ¼ antiretroviral therapy; NRTI ¼ nucleoside reverse
transcriptase inhibitor; NNRTI ¼ non-nucleoside reverse transcriptase inhibitor;
PI ¼ protease inhibitor

The vast majority of patients treated with NRTIs received a combination of two
NRTIs (mostly AZT þ 3TC)
†
The vast majority of patients received a boosted PI
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viral genotypic resistance test in patients who were off treat-
ment for more than six months.
Because our study was based on a convenience sample, we
were neither able to deﬁne how frequent drug interruption in
individuals with chronic HIV infection is occurring in these
clinics nor able to analyse individuals who stopped visiting
the clinics. Another limitation of this study was that we could
not obtain a sample before TI. Therefore, we do not know the
Table 2 Distribution of mutations associated with high- and low-level drug resistance in 38 long-term therapy interrupted patients
who developed viral resistance
Current mutations associated with resistance to
Sample
number
Pre-cessation
treatment
regimens
Months
after TI PIs NRTIs NNRTIs
Current drugs to which virus is
resistant based on genotype
Patient
decision for
interruption
1. AZT, 3TC, IDV,
RTV
6 M36I T215ST V106I AZT No
2. AZT, 3TC 6 L33V, L63P K70KR, K219KQ D4T AZT† No
3. DDI, D4T, IDV,
LPV/r
6 V32IV, L33FL, M46I,
I47IV, G73AT, I84V,
L90M, L10F, L63P,
I93L
M41L, E44D, D67N,
L74V, V118I,
L210W,T215Y,
K219R,
K103S, V108I,
G190A,
F227FL
3TC, FTC ABC†, AZT†, D4T†,
DDC
†
, DDI
†
, TDF
†
, DLV
†
,
EFV
†
, NEV
†
, ATV
†
, DRV
†
,
FPV
†
, IDV
†
, LPV
†
, NFV
†
,
SQV
†
, TPV
†
Yes
4. AZT, 3TC, EFV 6 L63P M184V K103N 3TC
†
, FTC
†
, DLV
†
, EFV
†
, NVP
†
5. AZT, 3TC, LPV/r 6 L10I, L63LPS, I93L K103KN,
P225HP
DLV
†
, EFV
†
, NVP
†
No
6. AZT, 3TC, LPV/r 6 M36I K103N DLV
†
, EFV
†
, NVP
†
Yes
7. AZT, 3TC, NFV 7 M36I T215N AZT, D4T, DDI Yes
8. AZT, DDC 7 M36I, L63S, K219KQ AZT No
9. AZT, DDC 8 L63P M41LM, V118IV,
L210W, T215D
ABC
†
, AZT
†
, D4T
†
, DDI
†
, TDF
†
No
10. AZT, 3TC 8 L63P, V177AITV M41LM, T215ST ABC, DDI, TDF AZT†, D4T† No
11. 3TC, D4T, NVP 8 M41LM, T215FIST TDF ABC†, AZT†, D4T†, DDI† No
12. AZT, 3TC 9 V77I K70KR AZT No
13. AZT, DDI 9 K20R, M36I, L63P T215Y ABC, DDI, TDF AZT†, D4T†, No
14. AZT, 3TC, EFV 9 M36I, L63LP K238KT EFV DLV†, NVP† No
15. D4T, 3TC, EFV 9 T215X Y188FHLY AZT, D4T, DDI DLV†, EFV†,
NVP
†
Yes
16. D4T, DDI, EFV 9 K20M, M36I, I93L K103N DLV
†
, EFV
†
, NVP
†
Yes
17. AZT, 3TC, EFV 9 M36I, L63T M41L, D67N,V118I,
L210W, T215Y
3TC, FTC ABC†, AZT†, D4T†,
DDI
†
, TDF
†
No
18. 3TC, DDC, D4T 10 L63P M184MV 3TC
†
, FTC
†
Yes
19. AZT, 3TC, EFV 10 L63P D67G K103N,
G190A
AZT DLV†, EFV†, NVP† Yes
20. AZT, DDI 10 M41L, L210W, T215D ABC
†
, AZT
†
, D4T
†
, DDI
†
, TDF
†
Yes
21. AZT, DDI, LPV/r 10 L63P, A71T AZT, D4TV No
22. D4T, 3TC, EFV 10 L63P, V77I G190EG DLV EFV†, NVP† Yes
23. AZT, DDI 11 M36I, V77I D67N, V118I, T215FL,
K219Q
K103R TDF ABC†, AZT†, D4T†, DDI† No
24. 3TC, D4T, SQV,
RTV
11 I54V, V82A, L90M,
L10I, K20R, M36I,
L63P, A71V
M41L, L118I, L210W,
T215H
DRV ABC†, AZT†, D4T†, DDI†,
TDF
†
, FPV
†
, IDV
†
, LPV
†
, NFV
†
,
SQV
†
, TPV
†
No
25. AZT, DDI, LPV/r 12 D30N, L63S, A71V,
I93L
T215Y ABC, DDI, TDF AZT†, D4T†,
NFV
†
Yes
26. AZT, DDI 12 L63P M41L, T69N, V118I,
L210W, T215C
3TC, FTC ABC†, AZT†, D4T†,
DDI
†
, TDF
†
No
27. AZT, 3TC, EFV 13 K20R, M36I K103N DLV
†
, EFV
†
, NVP
†
No
28. 3TC, D4T, NFV 13 D30N, N88D, L63P,
A71V, V77I
NFV
†
Yes
29. 3TC, D4T 13 M184V 3TC
†
, FTC
†
No
30. AZT, DDI 14 L63P D67G, K70R, L210F,
K219Q
AZT
†
, D4T
†
No
31. AZT, 3TC, LPV/r 15 M46L, L10F, V77I,
I93L
K103N, P225H ATV, FPV, IDV, LPV NFV†,
DLV
†
, EFV
†
, NVP
†
Yes
32. AZT, 3TC, EFV 16 V77I, I93L M184G Y188H,
G190D
3TC
†
, EFV
†
, DLV
†
, NVP
†
No
33. AZT, DDI 16 M36I, L63LP M41LM, T215ST ABC, DDI, TDF AZT†, D4T† No
34. 3TC, D4T 16 L63P, A71V, I93L K103N DLV
†
, EFV
†
, NVP
†
No
35. AZT, 3TC 22 M36I, L63P D67N, K219Q D4T AZT† No
36. AZT, DDI 27 V77I M41L, T215L ABC, DDI, TDF AZT†, D4T† No
37. AZT, 3TC, NVP 40 M41L AZT, D4T No
NRTI ¼ nucleoside reverse transcriptase inhibitor; NNRTI ¼ nonnucleoside reverse transcriptase inhibitor; PI ¼ protease inhibitor; AZT/ZDV ¼ zidovudine; 3TC¼ lamivudine;
EFV ¼ efavirenz; IDV ¼ indinavir; D4T ¼ stavudine; DDI ¼ didanosine; DLV ¼ delavirdine, NVP ¼ nevirapine, ABC ¼ abacavir, TDF ¼ tenofovir, FTC ¼ emtricitabine, SQV ¼
saquinavir, FPV ¼ fosamprenavir, TI ¼ treatment interruption
Minor mutations
†
Major mutations
................................................................................................................................................
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prevalence of resistance in this group under drug selection.
Nevertheless, we have evaluated actual patients who have
stopped their treatment on the base of medical recommen-
dations due to ART side-effects and toxicities.
Overall, we found that 27.7% of the patients in this group
harbour a drug-resistant strain. Besides viral load detectability
before drug interruption, no other variables could be correlated
with drug resistance. The pattern of resistance varied from few
to a complete set of mutations. This is notable because the
median time between TI and the genotype testing was 338
days, allowing for one of many different patterns to emerge
as a major species in these individuals and suggesting these
HIV variants are stable, at least in PBMCs, and have similar
ﬁtness to the wild-type virus. The viral load of these patients
rose to values similar to those before treatment, making it
more likely for them to transmit the virus. This fact, combined
with the history of unprotected sex, renders these patients a risk
for transmitting stable HIV-resistant strains.
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